**List of Review Article 2015-2016**\*\*\*2016\*\*\*

1. Ogawa Y, Ogura M, Tobinai K, Ando K, Suzuki T, Watanabe T, et al. A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma, Int. J. Hematol, 103:25-33, 2016
2. Iba T, Thachil J, Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan, Int. J. Hematol, 103: 253-61, 2016.
3. Nagai S, Ozawa K, Regulatory approval pathways for anticancer drugs in Japan, the EU and the US, Int. J. Hematol, 104:73-84, 2016
4. Maeda T, Regulation of hematopoietic development by ZBTB transcription factors, Int. J. Hematol, 104: 310-23, 2016
5. Yasunaga S, Ohno Y, Shirasu N, Zhang B, Suzuki-Takedachi K, Ohtsubo M, Role of Geminin in cell fate determination of hematopoietic stem cells (HSCs), Int. J. Hematol, 104: 324-29, 2016
6. Jiang Y, Chen Y, Huang R, Chen G, Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis, Int. J. Hematol, 104: 413-19, 2016
7. Mesa RA, Komrokji RS, Verstovsek S, Ruxolitinib dose management as a key to long-term treatment success, Int. J. Hematol, 104: 420-29, 2016
8. Feng Y, Li X, Xiao J, Li W, Liu J, Zeng X, et al. ADAMTS13: more than a regulator of thrombosis, Int. J. Hematol, 104: 534-39, 2016
9. Lin L, Wu M, Zhao J, The initiation and effects of plasma contact activation: an overview, 10.1007/s12185-016-2132-x

**\*\*\*2015\*\*\***

1. Miano M , Dufour C. The diagnosis and treatment of aplastic anemia: a review. Int. J. Hematol. 101: 527-35, 2015